AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. CLRB
  4. [Form 4] Cellectar Biosciences INC NEW Insider Trading Activity

[Form 4] Cellectar Biosciences INC NEW Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Positive)
Form Type
4
Rhea-AI Filing Summary

Form 4 highlights for Cellectar Biosciences (CLRB): On 07/02/2025, Chief Executive Officer and Director James V. Caruso purchased 10,000 shares of common stock at $4.99 per share. He simultaneously acquired 10,000 warrants exercisable at $5.25, expiring 07/02/2030, at a stated price of $0.01 per warrant. Following these transactions, Caruso directly owns 11,638 shares and 10,000 warrants. All share amounts reflect the 1-for-30 reverse split effected on 06/24/2025.

Punti salienti del Modulo 4 per Cellectar Biosciences (CLRB): Il 02/07/2025, il Direttore Generale e membro del Consiglio James V. Caruso ha acquistato 10.000 azioni ordinarie al prezzo di 4,99 $ per azione. Contestualmente, ha acquisito 10.000 warrant esercitabili a 5,25 $, con scadenza il 02/07/2030, al prezzo nominale di 0,01 $ per warrant. Dopo queste operazioni, Caruso possiede direttamente 11.638 azioni e 10.000 warrant. Tutte le quantit脿 di azioni tengono conto della divisione inversa 1-per-30 effettuata il 24/06/2025.

Aspectos destacados del Formulario 4 para Cellectar Biosciences (CLRB): El 02/07/2025, el Director Ejecutivo y miembro del consejo James V. Caruso 肠辞尘辫谤贸 10,000 acciones ordinarias a $4.99 por acci贸n. Simult谩neamente, adquiri贸 10,000 warrants ejercitables a $5.25, con vencimiento el 02/07/2030, a un precio declarado de $0.01 por warrant. Tras estas transacciones, Caruso posee directamente 11,638 acciones y 10,000 warrants. Todas las cantidades de acciones reflejan la divisi贸n inversa de 1 por 30 realizada el 24/06/2025.

Cellectar Biosciences (CLRB)鞚� Form 4 欤检殧 雮挫毄: 2025雲� 7鞗� 2鞚�, 斓滉碃瓴届榿鞛� 瓴� 鞚挫偓鞚� James V. Caruso臧� 氤错喌欤� 10,000欤�毳� 欤茧嫻 $4.99鞐� 毵れ垬頄堨姷雼堧嫟. 霃欖嫓鞐� 頄夓偓 臧�瓴╈澊 $5.25鞚搓碃 毵岆鞚检澊 2030雲� 7鞗� 2鞚检澑 10,000臧滌潣 鞗岆煱韸�毳� 欤茧嫻 $0.01鞚� 氇呺 臧�瓴╈溂搿� 旆摑頄堨姷雼堧嫟. 鞚� 瓯半灅 鞚错泟 Caruso電� 歆侅爲 11,638欤�鞕赌 10,000臧滌潣 鞗岆煱韸�毳� 氤挫湢頃橁碃 鞛堨姷雼堧嫟. 氇摖 欤检嫕 靾橂姅 2025雲� 6鞗� 24鞚检棎 鞁滍枆霅� 1雽� 30 鞎‰┐氤戫暕鞚� 氚橃榿頃� 靾橃箻鞛呺媹雼�.

Points cl茅s du Formulaire 4 pour Cellectar Biosciences (CLRB) : Le 02/07/2025, le Directeur G茅n茅ral et Administrateur James V. Caruso a achet茅 10 000 actions ordinaires au prix de 4,99 $ par action. Il a simultan茅ment acquis 10 000 bons de souscription exer莽ables 脿 5,25 $, expirant le 02/07/2030, au prix indiqu茅 de 0,01 $ par bon. 脌 la suite de ces transactions, Caruso d茅tient directement 11 638 actions et 10 000 bons. Tous les montants d鈥檃ctions tiennent compte du regroupement d鈥檃ctions au ratio de 1 pour 30 effectu茅 le 24/06/2025.

Form 4 Highlights f眉r Cellectar Biosciences (CLRB): Am 02.07.2025 erwarb der Gesch盲ftsf眉hrer und Direktor James V. Caruso 10.000 Stammaktien zu einem Preis von 4,99 $ pro Aktie. Gleichzeitig erwarb er 10.000 Warrants, aus眉bbar zu 5,25 $, mit Ablaufdatum 02.07.2030, zu einem angegebenen Preis von 0,01 $ pro Warrant. Nach diesen Transaktionen besitzt Caruso direkt 11.638 Aktien und 10.000 Warrants. Alle Aktienzahlen ber眉cksichtigen die 1-zu-30 Aktiensplit-R眉ckf眉hrung, die am 24.06.2025 durchgef眉hrt wurde.

Positive
  • CEO insider purchase: 10,000 shares bought at $4.99 on 07/02/2025 increases direct ownership to 11,638 shares.
  • Additional leverage: Acquisition of 10,000 five-year warrants at a $5.25 strike provides long-term alignment with shareholders.
Negative
  • None.

Insights

TL;DR: CEO bought 10k shares and 10k warrants, modest but constructive insider buying.

The Form 4 shows direct, open-market purchases by the company鈥檚 highest-ranking executive. Although the dollar value is limited (~$50k for equity plus nominal warrant cost), the transaction increases insider alignment and occurs shortly after a 1-for-30 reverse split, signalling confidence in post-split valuation. The warrants鈥� five-year life gives long-dated upside exposure. No sales were reported, and ownership now totals 11,638 shares (post-split). Given the small float typical of micro-cap biotech names, even incremental insider accumulation can be directionally positive.

Punti salienti del Modulo 4 per Cellectar Biosciences (CLRB): Il 02/07/2025, il Direttore Generale e membro del Consiglio James V. Caruso ha acquistato 10.000 azioni ordinarie al prezzo di 4,99 $ per azione. Contestualmente, ha acquisito 10.000 warrant esercitabili a 5,25 $, con scadenza il 02/07/2030, al prezzo nominale di 0,01 $ per warrant. Dopo queste operazioni, Caruso possiede direttamente 11.638 azioni e 10.000 warrant. Tutte le quantit脿 di azioni tengono conto della divisione inversa 1-per-30 effettuata il 24/06/2025.

Aspectos destacados del Formulario 4 para Cellectar Biosciences (CLRB): El 02/07/2025, el Director Ejecutivo y miembro del consejo James V. Caruso 肠辞尘辫谤贸 10,000 acciones ordinarias a $4.99 por acci贸n. Simult谩neamente, adquiri贸 10,000 warrants ejercitables a $5.25, con vencimiento el 02/07/2030, a un precio declarado de $0.01 por warrant. Tras estas transacciones, Caruso posee directamente 11,638 acciones y 10,000 warrants. Todas las cantidades de acciones reflejan la divisi贸n inversa de 1 por 30 realizada el 24/06/2025.

Cellectar Biosciences (CLRB)鞚� Form 4 欤检殧 雮挫毄: 2025雲� 7鞗� 2鞚�, 斓滉碃瓴届榿鞛� 瓴� 鞚挫偓鞚� James V. Caruso臧� 氤错喌欤� 10,000欤�毳� 欤茧嫻 $4.99鞐� 毵れ垬頄堨姷雼堧嫟. 霃欖嫓鞐� 頄夓偓 臧�瓴╈澊 $5.25鞚搓碃 毵岆鞚检澊 2030雲� 7鞗� 2鞚检澑 10,000臧滌潣 鞗岆煱韸�毳� 欤茧嫻 $0.01鞚� 氇呺 臧�瓴╈溂搿� 旆摑頄堨姷雼堧嫟. 鞚� 瓯半灅 鞚错泟 Caruso電� 歆侅爲 11,638欤�鞕赌 10,000臧滌潣 鞗岆煱韸�毳� 氤挫湢頃橁碃 鞛堨姷雼堧嫟. 氇摖 欤检嫕 靾橂姅 2025雲� 6鞗� 24鞚检棎 鞁滍枆霅� 1雽� 30 鞎‰┐氤戫暕鞚� 氚橃榿頃� 靾橃箻鞛呺媹雼�.

Points cl茅s du Formulaire 4 pour Cellectar Biosciences (CLRB) : Le 02/07/2025, le Directeur G茅n茅ral et Administrateur James V. Caruso a achet茅 10 000 actions ordinaires au prix de 4,99 $ par action. Il a simultan茅ment acquis 10 000 bons de souscription exer莽ables 脿 5,25 $, expirant le 02/07/2030, au prix indiqu茅 de 0,01 $ par bon. 脌 la suite de ces transactions, Caruso d茅tient directement 11 638 actions et 10 000 bons. Tous les montants d鈥檃ctions tiennent compte du regroupement d鈥檃ctions au ratio de 1 pour 30 effectu茅 le 24/06/2025.

Form 4 Highlights f眉r Cellectar Biosciences (CLRB): Am 02.07.2025 erwarb der Gesch盲ftsf眉hrer und Direktor James V. Caruso 10.000 Stammaktien zu einem Preis von 4,99 $ pro Aktie. Gleichzeitig erwarb er 10.000 Warrants, aus眉bbar zu 5,25 $, mit Ablaufdatum 02.07.2030, zu einem angegebenen Preis von 0,01 $ pro Warrant. Nach diesen Transaktionen besitzt Caruso direkt 11.638 Aktien und 10.000 Warrants. Alle Aktienzahlen ber眉cksichtigen die 1-zu-30 Aktiensplit-R眉ckf眉hrung, die am 24.06.2025 durchgef眉hrt wurde.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
CARUSO JAMES V
(Last) (First) (Middle)
C/O CELLECTAR BIOSCIENCES, INC.
100 CAMPUS DRIVE
(Street)
FLORHAM PARK NJ 07932
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Cellectar Biosciences, Inc. [ CLRB ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Executive Officer
3. Date of Earliest Transaction (Month/Day/Year)
07/02/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 07/02/2025 P 10,000 A $4.99 11,638(1) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Warrants $5.25 07/02/2025 P 10,000 07/02/2025 07/02/2030 Common Stock 10,000 $0.01 10,000 D
Explanation of Responses:
1. This number has been adjusted for the one-for-thirty (1:30) reverse stock split effected by the Issuer on June 24, 2025.
/s/ Christina Blakley, attorney-in-fact for James V. Caruso 07/03/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

How many Cellectar Biosciences (CLRB) shares did the CEO purchase?

James V. Caruso bought 10,000 shares of CLRB common stock on 07/02/2025.

At what price were the CLRB shares acquired?

The open-market purchase price was $4.99 per share.

What derivative securities were involved in the transaction?

Caruso acquired 10,000 warrants exercisable at $5.25, expiring on 07/02/2030.

How many CLRB shares does the CEO own after the transaction?

He now directly owns 11,638 shares (post 1:30 reverse split adjustment).

When did Cellectar Biosciences conduct its reverse stock split?

A 1-for-30 reverse split was effected on 06/24/2025, and the Form 4 figures reflect this adjustment.
Stock CLRB logo
Cellectar Biosciences Inc

NASDAQ:CLRB

CLRB Rankings

#8850 Ranked by Market Cap
N/A Ranked by Dividends
#124 Top Gainer

CLRB Latest News

Jul 2, 2025
Cellectar Biosciences Announces Closing of $6.9 Million Underwritten Public Offering, including Full Exercise of Over-Allotment Option
Jul 1, 2025
Cellectar Biosciences Announces Pricing of $6 Million Underwritten Public Offering
Jun 26, 2025
Cellectar Biosciences and U.S.-based Nusano Enter Into聽Multi-Isotope Supply Agreement
Jun 24, 2025
Cellectar Biosciences Submits Phase 1b Clinical Trial Protocol to US Food and Drug Administration for CLR 125 to Treat Triple-Negative Breast Cancer (TNBC)
Jun 18, 2025
Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split

CLRB Latest SEC Filings

Jul 3, 2025
[Form 4] Cellectar Biosciences INC NEW Insider Trading Activity
Jul 3, 2025
[Form 4] Cellectar Biosciences INC NEW Insider Trading Activity
Jul 1, 2025
[424B4] Cellectar Biosciences INC NEW Prospectus Filed Pursuant to Rule 424(b)(4)
Jul 2, 2025
[EFFECT] Cellectar Biosciences INC NEW SEC Filing
Jun 30, 2025
[S-1/A] Cellectar Biosciences INC NEW Amends IPO Registration Statement

CLRB Stock Data

13.37M
1.79M
1.64%
11%
4.27%
Biotechnology
Pharmaceutical Preparations
United States
FLORHAM PARK